

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number  
**WO 2005/044250 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/18**,  
31/255, 31/27, A61P 3/04, 3/10

Linda, Karen [GB/GB]; AstraZeneca R & D Alderley,  
Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number:  
PCT/GB2004/004582

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 28 October 2004 (28.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0325192.3 29 October 2003 (29.10.2003) GB

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except MG, US*): AS-  
TRAZENECA AB [SE/SE]; S-SE-151 85 Sodertalje (SE).

(71) Applicant (*for MG only*): ASTRAZENECA UK LIM-  
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-  
don W1K 1LN (GB).

**Published:**


— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BUDD HAEBER-  
LEIN, Samantha, Louise [GB/SE]; AstraZeneca R &  
D Sodertalje, S-SE-151 85 Sodertalje (SE). BUCKETT,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY



(57) Abstract: The use of a compound of Formula (I): wherein for example: X and Y are independently selected from: oxygen, sulphur and  $(\text{-CR}^a\text{R}^b\text{-})_n$ ; wherein: n is an integer of from 1 to 4 and  $\text{R}^a$  and  $\text{R}^b$  are each independently selected from hydrogen,  $\text{C}_{1-6}$ alkyl,  $\text{C}_{1-6}$ alkoxy, halo, hydroxy,  $\text{C}_{1-6}$ alkanoyloxy,  $\text{C}_{3-12}$ cycloalkyl and optionally substituted phenyl or  $\text{R}^a$  and  $\text{R}^b$  together form a  $\text{C}_{5-12}$ spirocycloalkyl or a carbonyl;  $\text{R}^1$  and  $\text{R}^3$  are independently selected from (a) optionally substituted phenyl or phenoxy; (b) optionally substituted naphth-1-yl or naphth-2-yl; (c) aryl $\text{C}_{1-6}$ alkyl; (d)  $\text{C}_{1-20}$ alkyl or  $\text{C}_{1-20}$ alkenyl; and (e) adamantyl or a  $\text{C}_{3-12}$ cy-  
cloalkyl  $\text{R}^2$  is hydrogen, a  $\text{C}_{1-6}$ alkyl or benzyl; or pharmaceutically acceptable salt, pro-drug or solvate thereof as DGAT inhibitors and in the manufacture of a medicament for the treatment of type II diabetes and/or obesity.